Calendrier des promotions Lisata Therapeutics, Inc.
Calendrier avancé
Graphique simple
À propos de l'entreprise Lisata Therapeutics, Inc.
Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other diseases. Its product candidates include LSTA1, which is in Phase 1b/2a and 2b clinical studies for the treatment of solid tumor, including metastatic pancreatic ductal adenocarcinoma (mPDAC), in combination with a range of anti-cancer regimens; HONEDRA, a recipient of SAKIGAKE designation critical limb ischemia; XOWNA that is in Phase IIb clinical trial for the treatment of coronary microvascular dysfunction; and LSTA201, a CD34+ cell therapy for the treatment of chronic kidney disease. The company was formerly known as NeoStem, Inc. and changed its name to Caladrius Biosciences, Inc. in June 2015. The company was formerly known as Caladrius Biosciences, Inc. and changed its name to Lisata Therapeutics, Inc. on September 15, 2022. Lisata Therapeutics, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.Paramètres de base
IPO date
1999-03-01
ISIN
US1280583022
Industry
Biotechnology
Sector
Health Care
Валюта
usd
Валюта отчета
usd
Сайт
Grade
Sous-estimation
Nom | Signification | Grade |
P/S | 24.49 | 1 |
P/BV | 0.8353 | 9 |
P/E | 0 | 0 |
Efficacité
Nom | Signification | Grade |
ROA | -44.56 | 0 |
ROE | -51.43 | 0 |
ROIC | 0 | 0 |
Dividendes
Nom | Signification | Grade |
Rendement en dividendes | 0 | 0 |
DSI | 0 | 0 |
Croissance moyenne du dividende | 0 | 0 |
Devoir
Nom | Signification | Grade |
Debt/EBITDA | -0.0066 | 10 |
Debt/Ratio | 0.0039 | 10 |
Debt/Equity | 0.1939 | 10 |
Impulsion de croissance
Nom | Signification | Grade |
Rentabilité Revenue, % | -94.43 | 0 |
Rentabilité Ebitda, % | 7.9 | 1 |
Rentabilité EPS, % | -69.67 | 0 |
paper.price.prices
Prix | Common.min. | Common.max. | Changement | paper.changes_in_industry | paper.changes_in_index | |
common.calendar.number_days.1 | 2.5 $ | 0 $ | 0 $ | 0 % | 0 % | 0 % |
common.calendar.number_days.7d | 2.46 $ | 0 $ | 0 $ | 1.42 % | 0 % | 0 % |
common.calendar.number_days.30d | 2.7 $ | 2.46 $ | 2.69 $ | -7.59 % | 0 % | 0 % |
common.calendar.number_days.90d | 1.95 $ | 1.9 $ | 2.74 $ | 27.95 % | 0 % | 0 % |
common.calendar.number_days.180d | 2.6 $ | 1.9 $ | 3.9 $ | -4.04 % | 0 % | 0 % |
common.calendar.number_days.1y | 2.75 $ | 1.9 $ | 3.9 $ | -9.27 % | 0 % | 0 % |
common.calendar.number_days.3y | 7.4 $ | 0.48 $ | 7.66 $ | -66.28 % | 0 % | 0 % |
common.calendar.number_days.5y | 2.45 $ | 0.41 $ | 7.66 $ | 1.84 % | 0 % | 0 % |
common.calendar.number_days.10y | 0.41 $ | 0.41 $ | 8.64 $ | 608.54 % | 0 % | 0 % |
common.calendar.number_days.ytd | 2.71 $ | 1.9 $ | 3.9 $ | -8.07 % | 0 % | 0 % |
Principaux propriétaires
Entreprises similaires
P/E & P/BV
Gestion d'entreprise
Superviseur | Titre d'emploi | Paiement | Année de naissance |
Dr. David J. Mazzo B.A. (Hons), B.Sc. (Hons.), M.Sc., Ph.D. | President, CEO & Director | 1.16M | 1957 (68 années) |
Dr. Kristen K. Buck M.D. | Executive VP of R&D and Chief Medical Officer | 938.42k | 1974 (51 année) |
Mr. James Nisco | Senior VP of Finance, Treasurer, CAO & Principal Financial and Accounting Officer | N/A | 1971 (54 année) |
Mr. Tariq Imam | Vice President of Business Development & Operations and Corporate Counsel | N/A | |
Mr. Gregory S. Berkin | Chief Information Officer | N/A | |
Mr. John D. Menditto | Vice President of Investor Relations & Corporate Communications | N/A | |
Ms. Gail Holler | Vice President of Human Resources | N/A | 1959 (66 années) |
Dr. William K. Sietsema Ph.D. | Vice President of Global Regulatory Affairs | 350.55k | 1956 (69 années) |
Informations sur l'entreprise
Adresse: United States, Basking Ridge. NJ, 110 Allen Road - Ouvrir dans google maps, Ouvrir les cartes yandex
Site web: https://www.lisata.com
Site web: https://www.lisata.com